Osteoporosis

Romosozumab is being investigated to treat postmenopausal women with osteoporosis.

Tymlos, an injection that treats postmenopausal women with osteoporosis, may incrase the risk of osteosarcoma.

Patients seeking treatment with the same drugs may face different out-of-pocket costs.

Bone turnover markers could tell a physician whether or not a patient is adhering to oral bisphosphonates.

In pharmacy school, I was taught to see if there was a cause when I learned of a patient?s adverse reaction, because if I?m treating the problem without removing the cause, the problem will still persist. In this situation, I couldn?t remove the cause. If I were to request that the doctor stop prescribing the calcium supplements, the elderly patient would be at higher risk for osteoporosis. If I can?t remove the cause, what can I do in this type of situation?

Abaloparatide can prevent bone fractures in postmenopausal women with osteoporosis.

Development of odanacatib has been discontinued, and regulatory approval will not be sought.

Approximately 14% of women who took calcium supplements developed dementia.

CBCT/CMOS can image trabecular bone more easily than the current method.

Approximately 1 in 2 women and up to 1 in 4 men 50 years and older will break a bone due to osteoporosis.

The drug binds to sclerostin and increases bone formation for osteoporosis in postmenopausal women.

The Bone Balance Index can strongly predict patients at risk for bone loss after menopause.

RANK-inhibitor denosumab was able to stop cell growth and reduce cancer development in breast cancer samples with mutated-BRCA1.

Top news of the day from across the healthcare landscape.

Little clinical guidance exists on how soon after a fracture occurs that osteoporosis medications should be prescribed.

Abaloparatide-SC found to boost bone mineral density in osteoporosis.

Evista is typically given to women after menopause to treat and prevent osteoporosis and reduce the risk of invasive breast cancer.

The FDA has approved Glenmark Pharmaceuticals Inc's abbreviated new drug application for raloxifene hydrochloride tablets USP, 60 mg, which is the therapeutic equivalent to Eli Lilly and Company's Evista.

Totaling more than 2 million, women comprise the fastest-growing group within the veteran population.

Less is more for women receiving osteoporosis drug therapy, as new research suggests that this patient population may be overtreated.

Too much calcium can't be good, right?

Teva recently launched risedronate sodium tablets, the generic version of Actavis's Actonel bisphosphonate, in 3 dosage strengths.

Women with the greatest risk for osteoporosis are not being screened enough, while those at less risk are being screened too often.

Gastroprotective agents may be needed in postmenopausal women taking bisphosphonates.

Controlling seizures is critical for patients with epilepsy, but side effects of antiepileptic drugs are another tremendous concern.